#114 - Eileen White, Ph.D.: Autophagy, fasting, and promising new cancer therapies
Episode Stats
Length
1 hour and 59 minutes
Words per Minute
155.90825
Summary
Dr. Eileen White is the Deputy Director and Chief Scientific Officer at the Rutgers University Cancer Institute and the Associate Director for Basic Research and the Co-Lead of the Cancer Metabolism and Growth Research Program at Rutgers University in New Jersey. She received her bachelor's degree from RPI and her PhD from SUNY and Stony Brook and did her postdoc with Bruce Stillman at Cold Spring Harbor Laboratory. Her early work focused on apoptosis, but it was doing some of the work there that she stumbled upon autophagy. And that is the focus of our discussion today.
Transcript
00:00:00.000
Hey everyone, welcome to the drive podcast. I'm your host, Peter Atiyah. This podcast,
00:00:15.480
my website and my weekly newsletter all focus on the goal of translating the science of longevity
00:00:19.800
into something accessible for everyone. Our goal is to provide the best content in health
00:00:24.600
and wellness full stop. And we've assembled a great team of analysts to make this happen.
00:00:28.880
If you enjoy this podcast, we've created a membership program that brings you far more
00:00:33.280
in-depth content. If you want to take your knowledge of the space to the next level at
00:00:37.320
the end of this episode, I'll explain what those benefits are. Or if you want to learn more now,
00:00:41.720
head over to peteratiyahmd.com forward slash subscribe. Now, without further delay,
00:00:47.740
here's today's episode. I guess this week is professor Eileen White. Eileen is the deputy
00:00:54.840
director and chief scientific officer, along with the associate director for basic research.
00:00:58.880
And the co-leader of the cancer metabolism and growth research program at Rutgers University
00:01:04.220
Cancer Institute in New Jersey. She received her bachelor's degree from RPI and her PhD from SUNY
00:01:10.200
and Stony Brook and did her postdoc with Bruce Stillman at Cold Spring Harbor Laboratory. Eileen's
00:01:15.300
early work focused on apoptosis, but it was doing some of the work there that she stumbled upon
00:01:21.020
autophagy. And that is the focus of our discussion today. Now, if you're even remotely familiar with this
00:01:27.320
podcast, you'll certainly know that the concept of autophagy has come up on so many previous
00:01:32.060
episodes. It is a fundamental pillar of health and maintenance of health. We talk a lot about it in
00:01:39.160
the context of fasting in particular. I have wanted to sit down with Eileen for a really long time,
00:01:45.120
and I don't think this conversation disappoints, although we certainly could have gone longer.
00:01:49.300
In this discussion, we talk about Eileen's career and how it morphed from studying apoptosis into
00:01:56.260
autophagy. We go into describing the regulation of autophagy, both metabolically and otherwise.
00:02:03.640
And then we spend a lot of time talking about the role autophagy plays in both the prevention of
00:02:09.420
disease and also the treatment of disease. And I think this is where it gets really interesting,
00:02:14.400
especially around cancer. And I think that that's potentially one of the most confusing
00:02:18.380
aspects of the entire discussion on autophagy. And that's actually one of the reasons I really
00:02:23.180
wanted to talk to Eileen was to better understand something that at the surface seems confusing to
00:02:29.440
me, which is that autophagy seems to very clearly protect a person or an organism from getting cancer.
00:02:37.420
Yet once someone has cancer, it appears that autophagy may disproportionately benefit the cancer
00:02:43.880
cell versus the non-cancer cell. So we tease this idea apart along with talking
00:02:48.340
about the amazing work that her lab has done to demonstrate the importance of autophagy in
00:02:53.980
preventing Alzheimer's disease and neurodegeneration, along with the benefits of metabolic health.
00:02:58.940
And of course, we do talk about the age old question that many of you have heard me
00:03:02.520
go on and on about, which is how do we delineate and understand the dosing and frequency of fasting as
00:03:10.100
a tool? In other words, when I talk about doing a fast of three days every month versus seven days,
00:03:15.060
a quarter versus five days, a quarter, how could we possibly get a handle on what the ideal strategy
00:03:21.180
is? And so we talk a lot about that as well. And I'm actually quite hopeful that from this
00:03:25.580
discussion comes some research that can shed light on that. So without further delay, I hope you enjoy
00:03:41.040
Eileen, thank you so much for extending your trip in San Diego for a day to come and make time to talk
00:03:46.880
with me about this stuff today. Oh, it's my pleasure. I'm looking forward to it.
00:03:50.560
I don't know if you remember this, by the way, but David Sabatini introduced us a few years ago. Do you remember?
00:03:55.560
I do. I still have my notes from that phone call five years ago. I took about 20, maybe not 20,
00:04:02.440
that's an exaggeration, maybe 10 pages of notes in my journal and probably have gone back to those
00:04:08.380
a dozen times in the last five or six years. So I always appreciate it when people just pick up the
00:04:14.060
phone and talk to total strangers for no reason. So that's greatly appreciated.
00:04:17.780
Well, you were excited about the science. And so nerds like me like to talk about science.
00:04:24.080
Well, let's actually start from there. Tell me where your interest in science came from.
00:04:29.160
Was it something that was always in you from a young age? Were you just naturally curious?
00:04:33.300
Yeah, I've been asked that question many times before. I come from a family where there was an
00:04:39.560
interest in science. My mother was a elementary school teacher and my father was a lawyer, but he
00:04:47.340
always wanted to be in science. And all of our discussions were related a lot to new scientific
00:04:58.000
discovery. So from an early age, I was introduced to science, which was probably unusual.
00:05:04.420
And I then went to college and majored in science and biology and continued from there. And I decided
00:05:14.300
when I was an undergraduate, I wanted to get a PhD in biology. And I was very fortunate to
00:05:21.100
go into graduate school in the department led by Dr. Arnie Levine, who discovered P53. And that was an
00:05:31.100
inspirational experience because he has got scientific insight that's absolutely incredible.
00:05:37.360
And then I went on to Quiltspring Harbor Lab, where I was a postdoc with Bruce Stillman.
00:05:43.760
And again, another incredible scientist, and it was an incredible scientific environment.
00:05:49.980
There were a whole cadre of investigators there that were making major contributions in the field of
00:05:58.260
cancer at the time. And it was just a very thrilling experience to be in an environment where
00:06:04.040
once a week, there was some fabulous discovery and everyone was excited about it. There were even,
00:06:10.400
I think, two Nobel Prizes awarded while I was there. And I joined the faculty at Cold Spring Harbor
00:06:16.120
after that. And then I moved on to Rutgers. And I had the fortunate experience of building a cancer
00:06:23.880
center. So when I went to Rutgers to be on the faculty, there was no cancer center. But shortly after I
00:06:30.660
arrived, they hired a cancer center director, Bill Height from Yale. And I joined him to help build what's
00:06:39.960
now the Rutgers Cancer Center or the Rutgers Cancer Institute, which went from nothing to now there are
00:06:47.500
multiple buildings, there are 11 hospitals in our health system. We have 240 something members of the
00:06:57.700
Rutgers Cancer Institute. And we have, we're a consortium cancer center with Princeton University.
00:07:03.440
And so it was very thrilling for me to not only have maintain my scientific interest by running a
00:07:10.740
research lab, but also help expand and grow something from nothing, where now we're treating large numbers of
00:07:20.000
patients in standard of care and clinical trials and making large discoveries and moving cancer
00:07:28.460
treatment, advancing cancer treatment as fast as we can.
00:07:34.420
I joined there in 1990. So I've been there for a long time, but I moved about 12 years ago. I moved from
00:07:41.280
one research building to be physically in the cancer center where I could be more directly helpful.
00:07:49.260
So where in your journey did autophagy pique your curiosity?
00:07:56.040
It was purely serendipity. So this goes back to when I was a postdoc with Bruce Stillman at Cold
00:08:02.900
Spring Harbor. I was given an oncogene to study. That time they had just sequenced the adenovirus genome.
00:08:10.800
They knew what genes caused cancer in the virus. I was given one of those genes and said,
00:08:18.080
figure out what it does. And that was a dream project for a postdoc. And what I found was that
00:08:23.940
this gene was a viral homologue of BCL2. BCL2 is a gene, it's a human oncogene, and it functions by
00:08:33.660
blocking apoptosis or programmed cell death. And so that was transformative to me and took other people
00:08:41.660
a while to realize the importance of that, that one novel function of cancer is to evade cell death.
00:08:51.120
That field grew. We and others contributed cloning the other genes that regulated apoptosis. We figured
00:08:59.680
out how it all, the mechanism by which it worked. And the pharmaceutical industry started developing
00:09:06.580
inhibitors of BCL2 to promote apoptosis and cancer. And that was the ultimate goal, was to make tumor
00:09:15.140
cells die and have a drug that will do that. And once that happened, the field of apoptosis, I think,
00:09:22.940
sort of, we accomplished what we wanted to accomplish. We understood everything. And that led to the
00:09:30.480
development of the first of many drugs that were in clinical trials. And in fact, my lab is still
00:09:36.980
involved with taking those drugs and putting them in patients and optimizing their use in solid tumors.
00:09:44.280
So while the field of apoptosis matured to the point where things were being translated,
00:09:54.280
we made a serendipitous discovery. We had engineered tumor cells to
00:10:00.200
be unable to undergo apoptosis. They were refractory to being able to commit suicide.
00:10:08.960
Can we pause for a second there, Eileen? And just let's explain to folks exactly how apoptosis works,
00:10:13.460
because shortly we're going to obviously contrast this with autophagy. They have common threads,
00:10:18.300
but they're different. So let's go down the path of what does it take to get a cell to undergo
00:10:24.100
programmed suicide? So there's a family of proteins called the BCL2 family. They come in different
00:10:31.440
flavors. There are the BCL2-like proteins, which inhibit apoptosis, so they keep tumor cells alive.
00:10:40.100
And BCL2 is a prototypical member of that family and is upregulated and amplified and translocated in
00:10:49.860
many cancers to do exactly that. And are antagonizers of BCL2 and its related proteins. These are called the
00:11:00.620
BH3-only proteins. And they are often activated to inhibit BCL2 to trigger apoptosis. And then there's
00:11:11.860
the core apoptotic machinery that triggers apoptosis. And this is backs and back. They reside in the
00:11:19.940
mitochondrial membrane. And when they're triggered to undergo apoptosis, they oligomerize and poke holes
00:11:28.840
in the mitochondrial outer membrane that releases proteins that activate proteases to grade the cell.
00:11:36.800
And BCL2 and BCLXL, all the anti-apoptotic proteins are involved in antagonizing this process.
00:11:45.480
And what are some of the things that would have to be going wrong in a cell for it to go down that
00:11:50.580
suicidal pathway? So for example, mitochondrial injury that is irreversible, genetic mutation that is
00:11:58.900
unfixable. Like what are the suite of things that basically take a cell down the path of,
00:12:04.960
I can't fix this and being around here and replicating is going to be dangerous to the host. I got to
00:12:10.680
take myself out of the game. Right. So mitochondrial damage can certainly trigger apoptosis. But probably
00:12:18.180
the best way to explain it is by using the example of P53. So P53 is a tumor suppressor and a
00:12:26.960
transcription factor. And some of the transcriptional targets of P53 are proteins like PUMA and NOXA,
00:12:36.460
which are these antagonizers of BCL2 and activators of backs and back. P53 is a tumor suppressor.
00:12:45.360
One of the functions is to promote apoptosis to prevent an emerging cancer cell from progressing.
00:12:53.400
One mechanism by which P53 does that is by turning on the transcription of PUMA and NOXA,
00:13:02.120
and then that will antagonize BCL2 and initiate apoptosis. So then the question becomes what
00:13:09.600
activates P53 to do that? And that could be a long list of things from DNA damage, from oxidative stress,
00:13:17.820
and so forth. So you could think of something bad happens to an emerging cancer cell, and then
00:13:24.820
P53 gets activated. And one of the tumor suppression functions of P53 is to turn on these promoters of
00:13:34.820
apoptosis that antagonize BCL2. Now, loss of function in P53 probably accounts for half of all cancers,
00:13:42.040
correct? Right. And I assume that you have to lose both copies of it, or is losing one copy sufficient?
00:13:48.940
Well, what happens in most of the time is not deletion of P53, but rather a point mutation.
00:13:57.240
That reduces function. It's more of a dominant negative. So in fact, there's even evidence that
00:14:02.640
there's a gain of function. So there are hotspot mutations in P53 that are very common in cancer,
00:14:09.900
and P53 functions as a heterodimer. And what these mutant P53s do is that they end up entering into a
00:14:20.580
dimer with wild-type subunits, and that interferes with the function of the complex. So yes, in that
00:14:27.280
respect, it can be a loss of function of the P53 heterodimer, but there's evidence that it not only
00:14:36.220
causes a loss of function, but it actually may do other things as well that are cancer-promoting.
00:14:42.300
That's just a great example of the nuance of evolution, right? I mean, in med school,
00:14:45.440
the classic teaching, you know, 100 years ago for me was P53, loss of function, oncogene,
00:14:51.040
gain of function, black and white. Of course, it's never black and white.
00:14:54.060
Right. So what is the wreckage of apoptosis? So when a cell undergoes apoptosis to everything
00:15:03.220
outside the cell, inclusive of the immune system, what becomes visible? In other words,
00:15:09.220
does an apoptotic cell, once it dies, elicit any immune response? Or does the process of
00:15:15.220
apoptosis yield sort of an inert body of cellular matter that just goes away?
00:15:20.240
I'm not so sure I'm the best person to answer that question. I think the whole idea initially was
00:15:26.880
during the process of apoptosis, you would get protein degradation and packaging of pieces of
00:15:34.540
the dead cells into these apoptotic bodies. And then that would reduce inflammation. And then there's
00:15:41.920
evidence that macrophages can then go and take up these apoptotic bodies. And that may facilitate
00:15:49.280
antigen presentation and so forth. So it's possible, for example, that if you have a cell
00:15:56.760
that has become cancerous, either through a gain of function, loss of function, but whatever,
00:16:01.100
there's some mutation that now renders this cell to go down a pathway of cancer.
00:16:06.060
Fortunately, it undergoes the apoptotic transition. The macrophages take it. Is it likely that you get an
00:16:13.860
immune response to that that is protective in the long run against similar mutations? Because
00:16:18.940
I mean, even though the macrophage is part of the innate immune system, does that ever translate to
00:16:22.780
the adaptive immune system such that you gain some long-term immunity from that specific type of
00:16:27.660
mutation? Yes. I think something like that occurs. And I'm just thinking I'm the wrong person to answer
00:16:33.640
that question. I could give you the better names of people that can do a better job. But I think the best
00:16:39.740
way to compare it is to contrast it with necrotic cell death. So in apoptosis, you have proteolytic
00:16:47.520
degradation and of a cell and packaging it into these bodies. And you say, well, does that limit
00:16:56.700
inflammation? Well, the way to explain how it does is to compare it to a different form of cell death,
00:17:02.760
like necrosis. So necrosis is cells, lice, and that is very pro-inflammatory. You have nucleic acids
00:17:12.380
released. You have essentially everything is released. Including mitochondrial content, which
00:17:17.820
is probably the most immunogenic given its bacterial origin of the DNA. Absolutely. And so
00:17:23.360
apoptosis, what I'm hearing you say is apoptosis is much cleaner than necrosis. Absolutely.
00:17:28.200
So now let's talk about autophagy. Let's contrast autophagy with apoptosis.
00:17:34.100
That's right. Well, before we get to that, I should go back to your original question of like,
00:17:37.960
how did we start working on autophagy? And this sort of bridges us to what you just mentioned. So
00:17:44.480
when we disable apoptosis in a cancer cell, it can't commit suicide. And we're doing that all the
00:17:52.080
time. And we could show that then the tumor cells become more tumorigenic. But what we
00:17:57.940
didn't expect was the extraordinary propensity for survival. We could leave the cells out and
00:18:07.820
put them in buffer. They wouldn't die under extraordinary circumstances that we couldn't
00:18:15.940
explain. So why would a cell that just couldn't commit suicide survive in buffer with no nutrients
00:18:23.840
at all? And just for context, this is the mid 80s, late 80s?
00:18:28.640
This is the mid 80s. No, it was probably later than that. It was probably early 1990s. And so
00:18:37.020
it was a conundrum. I mean, just because a cell can't commit suicide doesn't explain how it can
00:18:42.540
be a cancer cell can just sit in buffer and be fine. And we puzzled over this, like, how can this be?
00:18:50.380
And then we discovered that what these cells had done was turned on autophagy. And we're using that
00:18:58.700
for survival. Before you go down that path, help me understand something. What did you observe about
00:19:04.600
those cells that were sitting there in the absence of nutrients surviving? Did you notice any metabolic
00:19:09.680
changes that were unusual? Like, what was your clue that they were able to usurp the environment they
00:19:18.520
were in? It was an act of desperation. We tried a bunch of things and nothing was informative. And
00:19:26.580
then I told the people in the lab, why don't we just look at these cancer cells under the electron
00:19:31.900
microscope? And that way we can, we can see everything because we couldn't understand how
00:19:38.220
they could be surviving a buffer. And when we got the electron micrographs back, we saw something we
00:19:43.760
had never seen before. And all these double membrane vesicles all over the cell. And so that,
00:19:50.920
when we finally, all those are autophagosomes, which we had never, ever seen.
00:19:55.660
But wait, how did you, I mean, first of all, this is just to me, one of the beautiful moments in
00:20:00.380
science that I think, I think it's so important for people who don't do science for a living to
00:20:06.480
understand that while science is 99% failure, every once in a while, you have a moment like that.
00:20:13.340
Yeah. It probably makes up for 10 years of failure.
00:20:17.620
When you realize in that moment, you are seeing something that has never been seen before.
00:20:22.860
And therefore, this is the cusp of new knowledge.
00:20:26.900
That's right. That's happened to me a bunch of times in my career, which is fortunate. And this
00:20:32.420
was one of those moments. And then we started reading, oh, what are these autophagosomes? What do
00:20:37.440
they do? And then when we realized from when we looked in the yeast literature, they were
00:20:42.260
meant to capture intracellular proteins and organelles and bring them to the vacuole of the
00:20:49.220
mammalian lysosome for degradation and recycling. And that this was a mechanism by which yeast survived
00:20:56.940
And what was the tumor line or what was the cell line you were doing this in?
00:21:01.780
At the time, we were using kidney cancer cell lines.
00:21:08.480
But it was basically the first time this had been seen in mammalian cell line?
00:21:12.020
No, I think people had seen autophagosomes before. I mean, you've got to remember in the
00:21:16.920
olden days when electron microscopes were first available, that that's one of the things that
00:21:23.260
people did was describe all kinds of different processes. So autophagosomes were known to exist,
00:21:30.620
but there was very, very little information, almost no information on autophagy and cancer
00:21:36.400
at the time. So we went into this area where there was almost no information. And so the first question
00:21:44.180
we asked is, okay, well, the yeast data tells us that when you see autophagosomes, that means
00:21:51.280
cells are starved and they're recycling and they're using this to survive. And we hypothesized
00:22:00.780
that that's what was going on in these cancer cells. And if that was the case, if autophagy was a
00:22:07.820
survival pathway in cancer, that was a game changer. We had to understand it and we had to demonstrate
00:22:16.660
that that that's what was actually happening. And then if that was the case, if cancer cells had
00:22:23.740
usurped the autophagy pathway for their survival, then we needed to inhibit autophagy for cancer
00:22:32.020
therapy. The first thing we did was we looked to see what would happen if we inhibited autophagy
00:22:40.580
in these cancer cells? And the answer was very simple. In many, many circumstances and many
00:22:48.520
different cell lines that we looked at, when you inhibited autophagy, the survival of the cancer
00:22:53.840
cells was reduced. Let me interject for a second and ask a question. I don't know if you ever did
00:22:58.780
this experiment, but if you took the kidney line and the kidney cancer line, so basically the same
00:23:04.060
histology from the same tissue from the same animal, but one has the oncogenic properties and
00:23:10.540
one does not, and you put them in the identical nutrient deprived stress, can you quantify the
00:23:18.480
amount of autophagy or the efficiency with which those two cells undergo autophagy? In other words,
00:23:23.280
is cancer simply preserving the autophagy capacity that it had as a non-cancer cell,
00:23:31.700
but not enhancing it or not having any attenuation of it? Is it simply just, hey,
00:23:36.260
this just happens to be something that gets preserved as you go from non-cancer to cancer?
00:23:40.040
Or is there some qualitative or quantitative change in the character of autophagy as a cell mutates?
00:23:47.300
That's interesting. So let me see if I can unpack that. So if you have the general observation
00:23:54.120
is that normal cells in the fed state don't have autophagy on, it functions at a very,
00:24:02.800
very low level. And if you starve cells or mammals for nutrients, then there's a massive
00:24:11.200
upregulation of autophagy. What was striking about the cancer setting was that even in the fed state,
00:24:19.360
autophagy was elevated. Ah, so there is a fundamental difference there.
00:24:23.860
Yes. And then if you stress them, it goes up even further. But the problem is,
00:24:29.740
is that when it's already high, how much higher can it go?
00:24:33.260
And just to be clear, Eileen, this is in vitro. So you can't even make, when you said that,
00:24:38.780
the first thought that came to my mind was, well, maybe the reason is they're undergoing a different
00:24:43.020
stress, which is, for example, a vascular stress, a hypoxic stress, because, you know,
00:24:46.520
haven't got enough VEGF or they haven't created enough. In other words, the apoptosis is going up
00:24:51.960
despite being fed because there's something else that's impairing them. But if what you just said
00:24:56.440
is true in vitro, then that wouldn't explain that, would it? In other words, if they're not
00:25:01.160
limited for oxygen, if they're in a petri dish and this is happening, my hypothesis wouldn't make
00:25:06.100
sense. That would only make sense if what you said was true in vivo. Right. So in the fed state,
00:25:11.260
the cancer cells already have elevated autophagic flux. And when you fast them, it does go up, but
00:25:20.420
it's only so high it can go. I see. So this probably, you know, it's really funny. I'm sure
00:25:27.060
you're familiar with the paper that Matt Vander Heiden and Luke Hantley and Craig Thompson run in
00:25:30.280
Science in 2009, which was, at least to my knowledge, the first time that someone offered
00:25:35.300
an alternative explanation for the Warburg hypothesis, which is, hey, it might not be that
00:25:39.580
the mitochondria of the cancer cells are defective and can't undergo oxidative phosphorylation.
00:25:44.820
It might be that they're optimizing for growth as opposed to metabolism. They don't care as much
00:25:50.200
about ATP as they care about building blocks. And therefore they're deliberately taking an
00:25:55.880
inefficient route of glycolysis to lactate because they want the cellular building blocks. And that
00:26:02.980
might be the explanation here is that the tumor cell is undergoing more constant proliferation and
00:26:10.360
therefore they want more building block. Exactly right. And in fact, when we look at cancer cells and
00:26:17.780
we study their metabolism, what we've noticed, and this is something that we found, and it's been
00:26:23.560
a common observation, is that nucleotides seem to be rate limiting. And so the metabolism of a cancer
00:26:33.780
cell is designed to facilitate de novo synthesis of nucleotides. So that's really interesting,
00:26:40.980
isn't it? When you realize something about it, like you think of all the things that could potentially
00:26:44.340
be rate limiting to a cell. Think of how many phospholipids, for example, they need to build
00:26:48.980
all of those cell membranes. And yet it's the nucleic acid to continue to propagate its DNA
00:26:57.200
that becomes rate limiting. That to me is very interesting. I wouldn't necessarily have ever guessed
00:27:02.000
that. We may learn more as going forward, but that is what seems to be a recurring theme. But it's not
00:27:09.980
just DNA, it's also RNA. And you have to remember that RNA and ribosomes make up a huge amount.
00:27:16.840
They're a much greater demand. Exactly. And I think David Sabatini has mentioned this many times that
00:27:22.520
a large amount of the mass of a cell is ribosomal RNA. And he had a beautiful paper
00:27:29.620
where he was making the argument that ribophagy, the autophagy of ribosomes,
00:27:35.880
was an important metabolic survival mechanism. And you could think of ribosomes as being a depot,
00:27:42.920
a storage depot for not only nucleic acids, but also protein. And when a cell
00:27:50.140
is stressed or starved, it doesn't need to make protein. So it doesn't really need large numbers
00:27:56.280
of ribosomes. And so the autophagy pathway can cannibalize those ribosomes because they're
00:28:03.180
unnecessary. And then recycle all that protein and nucleic acids to support survival.
00:28:10.600
A moment ago, you mentioned, of course, that some of this had already been observed in yeast. And
00:28:14.340
the moment we start talking about things that are true in yeast and then true in animals,
00:28:18.640
mammals, for example, or higher-order animals, we're talking about a billion years of evolution
00:28:22.240
here. So this ranks as one of the few things that seems remarkably conserved over evolution.
00:28:28.760
As a general rule, that makes it very important. Do we have a sense of when this first showed up?
00:28:36.420
Again, I might be out of my league. I mean, I know it's certainly a big
00:28:40.120
function in yeast. Prior to yeast, I don't know.
00:28:44.440
Yeah, but it's amazing. I mean, it's in the category of mTOR.
00:28:48.880
Something that is so important that it just doesn't really seem to change over about a billion years.
00:28:56.680
That's right. And I think when you compare how yeast does autophagy and how mammals do autophagy and
00:29:03.100
what they're using it for, it just looks like mammalian version of autophagy is a little bit
00:29:09.320
more complicated. It's probably, they have probably more different circumstances where autophagy
00:29:17.060
might be necessary, but the basic process is surprisingly the same.
00:29:23.940
What are some of the other stresses that induce autophagy? And let's maybe just for the moment,
00:29:28.360
even start with just in a normal cell. So let me sort of re-synthesize what we've talked about.
00:29:33.380
Clearly, nutrient deprivation is one of the biggest triggers for autophagy. And I mean,
00:29:38.380
maybe just for the sake of time, I'll kind of throw this out there and you can correct me if I'm wrong,
00:29:43.380
but I've always sort of thought of this through three pathways at the sort of mechanistic level.
00:29:47.860
So you have sort of the mTOR pathway, which is mostly sensing amino acids. You have the
00:29:54.120
AMPK pathway, which is mostly sensing energy and ATP in general. And then you have sort of the
00:29:59.920
acetyl-CoA protein deacetylation pathway, which is also just basically sensing substrate of fatty
00:30:06.140
acid and glucose. Is that sort of a fair way to say that those are three ways that low nutrients can
00:30:13.080
still trigger the same pathway? Yeah. And I think you could add on to that
00:30:17.800
stresses that result in organelle damage, such as depolarization of mitochondria or dysfunction of
00:30:26.800
mitochondria, activation of protein misfolding and generation of protein aggregates. So I think
00:30:34.520
there's the things that are directly related to metabolic signaling that you've mentioned,
00:30:39.640
but then there are other stresses that also can tie into the autophagy pathway.
00:30:44.080
Are there other stresses like the nutrient that are stresses that come from outside the cell to
00:30:49.380
inside the cell? So the protein misfolding, the mitochondrial depolarization, those are things that
00:30:56.180
are occurring as damage within the cell that stress. Do we know anything, for example, about temperature?
00:31:01.120
Do heat shock proteins stimulate autophagy in extremes of temperature? Does exercise, I mean,
00:31:07.040
which obviously is in the short term quite stressful, how potent is that at inducing autophagy in a normal
00:31:12.880
cell? So temperature wise, I would fully expect that temperature extremes would induce protein
00:31:20.340
misfolding and induce autophagy as a remedy for that. But I don't recall any studies on that. In terms
00:31:28.980
of exercise, that's very well studied that exercise induces autophagy very potently. And you actually need
00:31:38.380
autophagy to, because exercise damages the muscle and autophagy is one of the processes that helps
00:31:46.160
mitigate the damage that occurs during exercise. What about hypoxia? Oh, potently. Hypoxia potently
00:31:54.000
induces autophagy. Wow. And in fact, one of the first things we did was when we looked at tumors,
00:32:00.280
tumors are well known to have hypoxia in the center. When we engineered tumor cells to
00:32:08.100
be genetically deficient for autophagy, and you look at them, they're completely hollow.
00:32:16.160
Meaning they have no organelles, nothing? Not the cells are hollow. The tumor is hollow. Oh, wow.
00:32:21.880
The further the cells get from a blood supply, meaning the more susceptible they are to hypoxia,
00:32:27.300
they're dead. Right. So if you take a tumor, if the middle is hypoxic, that's where your autophagy is
00:32:34.040
most active. And if you genetically ablate autophagy in the tumor, you end up with a hollow tumor
00:32:39.420
because the tumor cells in the middle don't survive. Yeah. So it does come back to this
00:32:44.400
idea that we talked about earlier about hypoxia being potentially one of the things that autophagy
00:32:49.000
is protecting cancer from. Absolutely. How easy is it to create an animal model that is unable to
00:32:55.620
undergo autophagy? How difficult is that from a knockout perspective? Well, it's been done and we've done
00:33:01.340
it and it can be done different ways. So the original mouse strains that were made were deficient
00:33:07.680
in either of two of essential autophagy genes, one called HG5 and another one called HG7. And these
00:33:15.660
mice were developed in Japan and these mice are born, but they fail to survive the neonatal starvation
00:33:24.460
period. So when mammals are born... Meaning once they are cut off from an umbilical nutrient source,
00:33:29.760
it's almost like they have a glycogen storage disease, you know, those conditions where you
00:33:33.600
can't produce any glycogen, it's uniformly fatal if not treated the moment you're cut off from an
00:33:38.940
umbilical source of nutrient. Right. So that neonatal starvation period between the cutoff of the
00:33:47.480
placenta and suckling is a common feature in mammals. And there's potent induction of autophagy during
00:33:56.580
that period. I can't speak for humans, but certainly I would think so. And in mice, that's exactly what
00:34:03.200
happens. And so these autophagy deficient newborn mice don't survive. Wow. That really, I mean, again,
00:34:11.500
I think that simply underscores the evolutionary preservation of something. If you knock it out,
00:34:17.100
it is uniformly fatal. Do not pass go. Do not collect $200. You're gone.
00:34:21.380
And then what we did was, you asked a different question. It was like, what happens in an adult
00:34:27.240
mouse? So in a newborn mouse, it's a very different situation because any newborn mammal,
00:34:34.880
they don't have any fat. They have no reserves. And so when the Japanese group did the extraordinary
00:34:41.620
thing of trying to force feed these autophagy deficient newborn animals, and they didn't extend
00:34:48.160
their survival very much. Now, is this Yoshinori's group?
00:34:51.620
This was Niburo Mizushima and the Kumatsu group, I believe. I think it was coming from those two labs.
00:35:02.040
They discovered that the mice died shortly after birth. And then they realized that, well,
00:35:09.360
they suspected they had a metabolic problem and they weren't suckling because they were probably too
00:35:15.440
ill by the time they would have been able to. So they force fed them and that allowed them to live
00:35:23.300
for 24 hours, but they still died anyway. And then are you able to induce an autophagy knockout in an
00:35:31.420
adult? Yeah. So that's what we did because we realized that the newborn animal is- It's just too
00:35:37.580
fragile. Too fragile. They have no nutrient reserves. And actually in the setting of cancer,
00:35:43.320
we're thinking of, you want to treat an adult with a tumor. So what's happening in autophagy in a
00:35:50.600
newborn animal isn't even relevant. And so we engineered mice where we can take an adult mouse
00:35:56.980
and give the mice a chemical so that an essential autophagy gene will be deleted throughout the entire
00:36:04.860
animal. So one day they're an adult mouse with autophagy. And then a few days later, they're an adult
00:36:11.500
mouse with no autophagy. And these mice were very extraordinary. They lived for two to three months
00:36:18.560
and then they died predominantly of neurodegeneration. Autophagy is very important in the brain over the
00:36:26.320
long term. But if we fasted the mice, they were all dead within 16 hours.
00:36:33.160
Let's unpack that again. That's pretty remarkable. So you take a normal mouse that's got through the
00:36:38.780
vulnerability period of infancy and you genetically knock out its capacity for autophagy. The first
00:36:45.560
thing you observe is if you fasted for 16 hours, which admittedly is a pretty long fast for a mouse,
00:36:49.920
that might be the equivalent of fasting a human for a week. But that degree of nutrient deprivation
00:36:55.440
is uniformly fatal. If you continue to feed them well, they only survive another couple of months
00:37:01.740
because they ultimately succumb to neurodegeneration, suggesting that the role of autophagy in preventing
00:37:09.280
neurodegeneration is essential. And it's really not surprising when you think about the role,
00:37:14.700
everything you talked about with protein misfolding. I mean, when you start to think
00:37:17.780
about the toxicities that are driving neurodegeneration, using Alzheimer's disease
00:37:22.880
specifically as an example, there's a lot of crap that's basically getting accumulated in neurons.
00:37:29.820
This would be an elegant way to suggest that autophagy is keeping that at bay.
00:37:34.740
Exactly right. So one other way of looking at it is what tissues are more autophagy dependent than
00:37:43.340
others? Exactly. Brain would be really important. And there are a few others. And what we've noticed
00:37:48.960
when we looked at the mouse, the lacked autophagy, when we genetically deleted the autophagy gene in
00:37:56.200
the adult mouse, was that there were tissues like the brain that were very sensitive. And there were
00:38:02.920
other tissues like the lungs that didn't have any phenotype. So wait, in other words, when those
00:38:09.120
animals ultimately die of neurodegeneration and you undergo the pathology analysis, obviously the brain
00:38:14.360
is where you see the cause of death. You're saying in the lung, it looked completely normal.
00:38:22.180
Liver was very sensitive. So it doesn't lead to the death of the mouse. So if you did a liver specific
00:38:30.360
knockout of an essential autophagy gene, those mice have theotosis and their liver gets huge and
00:38:37.440
whatever, but it doesn't kill them. I mean, they can live for quite a long time.
00:38:41.620
So you induce fatty liver disease. So again, suggesting that autophagy probably plays a role
00:38:47.580
in preventing fat accumulation in the liver. Exactly right. And also protein aggregate
00:38:52.580
formation. One of the other phenotypes of steatosis is the accumulation of these Mallory bodies,
00:38:59.400
which are large protein aggregates composed of a protein called P62. When you lose autophagy in the
00:39:06.360
liver, you're causing accumulation of fat accumulation of protein aggregates, but the liver manages to
00:39:14.640
tolerate it. The brain, however, is a different story. If you have post mitotic neurons where
00:39:22.240
they don't have the capacity, they don't have the capacity to do that. I mean, when they accumulate
00:39:29.240
Was there evidence that the brain in some last ditch effort to survive was undergoing more apoptosis
00:39:37.080
of neurons? Yes. That's a common feature of these animals is increased apoptosis in the brain. But
00:39:44.940
before that, you see all kinds of terrible things going wrong. This has been part of a major effort
00:39:50.980
to generate autophagy stimulators as a remedy or as a means to delay neurodegenerative diseases.
00:40:01.060
I want to come back to this later on in the discussion, but I'll just plant the seed now.
00:40:06.140
Obviously, fasting is one of the most potent stimulators of autophagy. I spend a lot of time
00:40:11.660
thinking about how does fasting fit into our toolkit of longevity? A big part of longevity,
00:40:19.760
in fact, probably the single most important piece of longevity when it comes to the lifespan aspect
00:40:24.660
of it. So, you know, you think of lifespan versus health span, how long you live versus how well you
00:40:28.260
live. On the how long you live front, I think it's very safe to say, based on all of the animal data
00:40:34.260
and frankly, all of the centenarian data, that the key to living longer is delaying the onset of
00:40:40.520
chronic disease. So even when you look at centenarians who are genetically gifted with tools to live
00:40:47.820
longer, if you unpack what the gift is, it's delaying the onset of the disease, not living
00:40:54.780
longer once you have the disease. So the centenarians, once they get cancer and once they get heart
00:40:59.340
disease, they die at about the same rate over the same duration as the rest of us schmucks.
00:41:04.040
The difference is they get those diseases 20 to 25 years later. And again, that suggests to me that
00:41:10.420
if you want to live longer, you have to delay the onset of these things, not live longer once you have
00:41:14.200
them. And so it's hard to think that fasting doesn't play an essential role in that. When you realize
00:41:21.740
the role that fasting plays in the mitigation of Alzheimer's disease and metabolic disease, of course,
00:41:28.180
what we're going to come back to in a second is cancer, which seems to be this conundrum. This is the
00:41:32.400
needle we're going to want to thread a little later down the line. I'll plant the seed now, but I do want
00:41:37.900
to come back to the idea of ways that we can also induce autophagy sort of pharmacologically or
00:41:45.000
chemically. The first thing that would jump to your mind is anything that mimics fasting. The first
00:41:49.800
thing that comes to mind would be metformin, rapamycin, things like that, that what we talked about
00:41:54.700
earlier, just for the listener to sort of tie this together, we talked about these huge pathways that tell
00:42:00.760
the body nutrients are scarce. So when mTOR activity is down, that's a sign that we're deficient in amino
00:42:08.200
acids, but we can also do that with rapamycin. When AMPK is up, that's the cell being told we're
00:42:15.480
deficient in ATP. Another way you can do that is to give metformin. We haven't talked about sirtuins yet.
00:42:21.400
Maybe I'll pause for a moment. Do we have any sense of what sirtuin activity does in autophagy?
00:42:26.940
I'm not familiar with that literature. Okay. I was going to say,
00:42:30.300
because then you could get into the whole NAD versus NADH ratios and how that might factor into
00:42:34.860
it. So again, I'm really curious about this through a clinical lens as well, which is what
00:42:40.160
is the suite of products, but almost just saying that out loud. So between the two of us, we remember
00:42:44.260
to come back to this, but I now kind of want to get back to your story, which is we've got these mice,
00:42:49.280
you've got this much more elegant experiment now, which is you're actually going after the phenotype
00:42:53.480
of interest, which is in an adult in which you inhibit autophagy. What was happening in that
00:42:58.980
animal if it had cancer? So did you ever do the experiment where you had an adult with cancer,
00:43:04.680
then you knock out autophagy? That's actually one of the reasons we made that mouse.
00:43:10.080
So we had two questions we wanted to answer. One was if you inhibited autophagy in an adult mouse,
00:43:17.940
what would happen? Because if they died in an hour, then targeting autophagy for cancer therapy
00:43:24.480
would be pointless. Especially if you can't do it specifically. That's right. So the answer was
00:43:29.460
they didn't die in an hour, they died in two or three months, which was actually good news,
00:43:33.860
because that meant that there was a potential window of opportunity for inhibiting autophagy for
00:43:40.800
cancer therapy. And I'm sorry, Eileen, when they died in two to three months, was it still from the
00:43:44.620
neurodegenerative disease? And did they still have cancer at the time of death? We had to first make
00:43:48.920
a mouse that lacked where we could switch off autophagy and find out what happened to that mouse.
00:43:54.800
Okay, so we did that. And we saw that they died of neurodegeneration two or three months,
00:44:00.680
which was good. They died immediately, then we would have stopped, there would be no point in trying
00:44:06.160
to make cancer on that animal. But we did learn that they were intolerant to fasting, which was
00:44:12.840
perfectly consistent with everything we knew about what autophagy functionally did. So then we moved
00:44:19.220
to the second step, was to do the experiment that you just suggested, to make cancer in that mouse.
00:44:27.540
And then after the mouse had cancer, to then shut the autophagy pathway off. And then to ask the key
00:44:34.340
question, which died first, the mouse or the tumor? And the answer was the tumor died first.
00:44:41.840
Wow. Okay, so then here's the gangster question. Once the tumor died, could you reactivate autophagy
00:44:48.560
to prevent the neurodegeneration? Or is it a one switch direction?
00:44:52.700
That required a different type of mouse model. So what we were doing was making a mouse with cancer.
00:44:59.520
And then once the mouse had lung cancer, in this case, we deleted an essential autophagy gene in the
00:45:06.140
entire mouse tumor and all. But the gene was gone. So it wasn't like we could turn autophagy back on
00:45:14.120
in that model. But since then, one of my trainees in collaboration with a lab in the UK, they have
00:45:21.180
developed a model where they can toggle autophagy off and then back on again. And what they've seen
00:45:29.360
is a remarkable capacity of the normal tissues to restore themselves. So the experiment would be to
00:45:38.020
have a mouse to induce an shRNA to a specific autophagy gene to down regulate the expression
00:45:45.920
and inhibit autophagy that way. And then later on, take that shRNA away or shut it off and restore
00:45:55.680
normal autophagy in the mouse. And you see a lot of capacity for the tissues to restore themselves
00:46:03.440
back to normal. So that experiment basically becomes the proof point that says targeting
00:46:12.460
autophagy in cancer makes sense. That's probably the most elegant description you could provide of that.
00:46:18.580
That's right. I think it would be better if we had specific targeted therapies against
00:46:25.660
some of the enzymes in the autophagy pathway, because these are all genetic experiments. And
00:46:32.060
it's not exactly the same. Right. You might not get the complete penetration with a drug.
00:46:37.580
Or inhibiting a protease is not exactly the same as deleting the gene. But this is all what's called
00:46:45.640
proof of principle that the concept of inhibiting autophagy in cancer is valid.
00:46:52.180
So what do we know today about what you've just described as it pertains to two things? So I want
00:47:00.720
to slice the data across two variables. The first is tissue type or histology of cancer. And the second
00:47:08.100
is underlying genetic mutation. So I know that a lot of what you're describing is clearly true in KRAS
00:47:14.600
mutation. What about other drivers? We and a number of other cancer labs that use genetically engineered
00:47:24.140
mouse models for cancer have been banging away at that for a number of years. And what we've learned is that
00:47:30.580
KRAS driven lung cancer and pancreatic cancer are extraordinarily autophagy dependent. And you do it, you know,
00:47:39.660
make the mouse models and the tumors are very susceptible to the functional loss of autophagy.
00:47:45.720
Can you briefly tell folks what a KRAS driven cancer does? Like what is it about the mutation that drives
00:47:51.720
the oncogenesis? So KRAS is a GTP binding protein that is responsible for activating what's called the
00:48:00.740
MAP kinase pathway. And this pathway is very key in driving cell proliferation. And so cancers
00:48:09.480
have a mutation in RAS or mutations in RAS that leave it in the GTP bound or on state. So there's
00:48:19.080
perpetual growth signaling through the MAP kinase pathway. Which of course is the hallmark of cancer,
00:48:25.160
which is it's unresponsive to cell signaling. And when you are fixed in the on position,
00:48:29.300
you can't turn off. And basically that is cancer. That's right. And what's particularly
00:48:34.960
interesting about RAS driven cancers is that we have been very unsuccessful in drugging RAS.
00:48:42.800
And there's recent hope that the cysteine, the particular subset of the mutations in RAS that
00:48:49.940
involve a cysteine residue, that there are now drugs that target that. There's hope after decades of
00:48:57.720
Is the primary issue in the failure to drug RAS that you can't do it without creating toxicity for
00:49:05.320
other cells that are non-cancer or that it has too many workarounds to whatever you put in place?
00:49:11.080
I think too many workarounds is a common problem. What they've done is that they said, okay,
00:49:16.860
if targeting RAS is difficult, then let's go downstream of RAS.
00:49:21.720
Right, right. So there are inhibitors of RAF, MEK, and ERK, which are downstream of RAS. And those are
00:49:29.600
actively in use in the clinic, but they seem to be not durably effective in RAS driven cancers because
00:49:41.060
Yeah. So are there mutations or mutant drivers of cancer that we know are not dependent on autophagy
00:49:52.680
Yeah. It seems like there's a spectrum. So RAS driven cancers are particularly sensitive.
00:49:59.620
BRAF driven cancers like BRAF V600E is a common BRAF oncogenic mutation. And those cancers are
00:50:09.160
particularly sensitive. And those, the ones that were examined were lung cancers and melanoma.
00:50:14.920
The BRAF V600E mutation melanoma is very common. Homologous recombination deficient breast cancers.
00:50:24.700
And those would be, well, I mean, those would be models of hereditary breast cancer. Those are very
00:50:30.980
sensitive to loss of autophagy. APC deficient colon cancer is another example.
00:50:38.920
What about non-APC driven colon cancer, which of course is the majority of it? What do we know about that?
00:50:44.920
I don't think I can remember seeing a paper. I remember the APC deficient model. That's in fact
00:50:54.360
Anything we know about prostate cancer or other hormone sensitive breast cancers?
00:50:59.700
So prostate cancer is sensitive. We did that work. And hormone sensitive breast cancer,
00:51:06.080
I'm not recalling right now, but there are a long list of cancers that are sensitive. The sensitivity
00:51:12.700
is not all equal. For example, BRAF driven cancers are very sensitive, more so than RAS driven lung
00:51:20.960
cancer. So you just compare lung, BRAF lung cancer to RAS lung cancer. The BRAF mutant lung cancer is more
00:51:28.440
sensitive. The most sensitive cancer that we've encountered is in fact, RAS driven lung cancer with
00:51:35.620
LKB mutations. And this makes a lot of sense too. So one of my trainees who has her own research lab
00:51:43.180
hypothesized that we sat down and we thought, what cancer would be, would you predict to be most
00:51:49.960
autophagy dependent? And it should be a cancer with loss of LKB1. LKB1 is a tumor suppressor gene
00:51:58.520
that's involved in activating AMP kinase. And AMP kinase activates autophagy as a survival mechanism to
00:52:07.400
low energy. And so there were a whole class of lung cancers that have lost LKB1. And as a result,
00:52:15.860
they can't activate this protective mechanism. This is Dr. Jessie Guo. She made this mouse model,
00:52:23.180
rash driven lung cancer without LKB1. And lo and behold, when you delete an essential autophagy gene,
00:52:30.580
you abrogate tumorigenesis. So it makes a huge amount of sense. LKB deficient rash driven lung
00:52:39.080
cancer is probably the number one sensitive tumor. So how do we reconcile these two observations
00:52:48.220
that almost seem to have a difficulty coexisting? So the first is everything you've just stated,
00:52:54.400
which is pretty clear and unambiguously suggesting that autophagy is at least for a number of cancers,
00:53:03.960
an important part of their survival and proliferation. And we contrast that with an
00:53:11.060
abundant body of literature that suggests that when you combine fasting, which is a potent
00:53:17.420
inducer of autophagy with chemotherapy, for example, you enhance its efficacy. And we can
00:53:23.900
speculate about why that might be the case. These two things, although not directly comparable,
00:53:30.100
seem a little bit at odds. How do you think about those things?
00:53:34.960
I would probably think about it in a slightly different way. So if you want to get at the two
00:53:40.880
different roles of autophagy, one is cancer cells usurping it and turning it on for their own
00:53:47.200
survival. Then the other side of it is when we know that autophagy is protective. We know what
00:53:54.460
happens if you have a mouse without autophagy. Many terrible things happen. It takes a while,
00:53:59.780
but the mice die of neurodegeneration. Can I interrupt for one second? I'm sorry to do this,
00:54:04.340
but I'll forget this question. I want to come right back to your thought. In those animals that
00:54:08.780
died of neurodegenerative disease after two to three months, did they show an increase in
00:54:14.140
tumor genesis in any other tissue? No, they don't. But if you make a mouse
00:54:20.140
where you bypass the neurodegeneration by knocking out an essential autophagy everywhere else,
00:54:27.680
okay, but not the brain, then those mice will get benign hepatomas, so benign tumors of the liver.
00:54:34.740
But that makes sense too. Think about autophagy in normal tissues. We know it's important because if you
00:54:41.520
knock autophagy out on a mouse, there's tissue-specific but gradual deterioration,
00:54:47.820
ultimately leading to neurodegeneration, and you end up with steatosis, fatty liver disease.
00:54:54.100
The brain phenotype can be explained, as we discussed before. Neurons in the brain need this
00:55:01.000
protein and organelle quality control function. They're post-mitotic. They have to have a way of
00:55:05.920
getting rid of the garbage. In the liver, what happens when you damage the liver?
00:55:18.960
Exactly. So you end up with, when you inactivate autophagy in the liver,
00:55:23.420
you end up with these chronic cycles of damage, repair, and chronic inflammation.
00:55:28.500
And that is oncogenic. And that's not, you know, it's particularly obvious in the liver.
00:55:37.820
So I think what this is telling us is something very important. It's telling us that a main function
00:55:44.960
of autophagy in tissue homeostasis is to preserve cellular function to be normal to prevent chronic
00:55:56.220
damage and inflammation. And tissues that are susceptible to cancer as a result of chronic
00:56:02.760
damage and inflammation, autophagy is highly protective.
00:56:07.400
Which again, think about how complicated this is. Now I'll bring us back to the question I posed
00:56:12.340
a moment ago, but using this example, why does NAFLD ultimately lead to cancer? Because if you have
00:56:18.060
enough accumulation of fat, you get enough inflammation, you're going to get a pedacellular
00:56:21.220
carcinoma. Same with pancreatic cancer. Highly, you know, this is why alcohol is such a horrible
00:56:26.420
molecule. So toxic to the pancreas, to the liver, and you sow those seeds of inflammation and lo and
00:56:33.420
behold, you're increasing this risk of cancer. So on the one hand, we know that autophagy helps
00:56:39.280
ameliorate that. It cleans that up. It buffers that. At the same time, we just realized a moment ago,
00:56:44.400
oh boy, once you do get pancreatic cancer, it's a KRAS-driven cancer, autophagy is helping it.
00:56:50.620
So now let's come back to the question I posed a moment ago that I so rudely interrupted you in
00:56:54.140
answering, which was, how do you reconcile these?
00:56:57.300
I think it's a matter of thinking of the role of autophagy in cancer as being context dependent.
00:57:02.560
On the one hand, functional autophagy can delay the onset of chronic damage and inflammation
00:57:10.620
that are known causes of cancer in particular tissues, such as the pancreas and the liver
00:57:16.340
amongst a few others. So I think that stimulating autophagy through fasting or through pharmacologic
00:57:25.920
means at one point can be thought of as preserving health. But once you have a cancer, I think it's a
00:57:33.140
different ballgame. And at that point, it's a completely different context. And in that setting,
00:57:42.360
what we've learned is inhibiting autophagy is preferentially damaging to the tumor compared
00:57:51.600
And then going back to the other literature, which looks at the efficacy of fasting combined
00:57:58.140
with chemotherapy, which is superior to just chemotherapy, do you think that the reason for
00:58:04.660
that is that the chemotherapy itself, maybe once you're rendering the cells more sensitive to
00:58:12.160
chemotherapy and also potentially generating a more durable immune response? Because one
00:58:16.920
interpretation of what you're saying is a person with cancer should never be calorically restricted.
00:58:21.240
I don't know. That's going too far. I would say that I don't know that you can equate caloric
00:58:29.140
restriction with the loss of autophagy or regulation of autophagy because I think they're not equal
00:58:36.780
things because I think that caloric restriction is limiting tumor nutrients. And so I think what that's
00:58:45.280
doing in the context of cancer therapy needs to be better understood. I'm just not sure that we know
00:58:56.120
If I'm hearing you correctly, you're saying, look, it might be that we can't necessarily say that
00:59:00.580
fasting isn't helpful in cancer because while it may be counterproductive from the standpoint of
00:59:07.300
autophagy, that may be offset by other things that are beneficial, such as the reduction of overall
00:59:11.780
nutrients and inflammation that accompany this.
00:59:15.540
Yeah. To me, of all of the areas of autophagy that have me scratching my head the most,
00:59:21.100
it is this question of, given that fasting is one of our most potent ways to stimulate it. In fact,
00:59:28.480
I would argue it's more potent than metformin, which is an AMPK activator, more potent probably
00:59:33.020
than exercise. I mean, it might be the most potent thing we can do to turn this amazing tool on.
00:59:37.740
How do we think about using it in disease prevention and disease treatment? And they aren't necessarily
00:59:43.520
I completely agree. And in fact, I would ask a question of you. So there's multiple efforts in
00:59:51.460
the biotech industry to identify pharmacologic agents that are potent stimulators of autophagy.
00:59:58.400
And I think their idea is, is that normal, healthy people will take a pill, autophagy will be turned
01:00:05.080
on, and there'll be some fountain of youth type thing.
01:00:09.420
Yeah. Spermidine is one of the things that people are talking a lot about, right?
01:00:12.500
So why not cultivate the use of fasting instead?
01:00:18.680
I will tell you exactly why, Eileen. And I love how you have fed into, it's almost like you can
01:00:24.580
read my mind and know where I'm going to go with this discussion. I think a big part of it is we
01:00:30.780
don't have the tools to measure the signatures of autophagy. In other words, if a patient comes to me
01:00:37.840
and says, Peter, I want to do whatever I can to enhance autophagy because I have now bought into the
01:00:45.280
idea that it is going to basically protect me from every chronic disease. And I would say,
01:00:50.180
yeah, I agree with you. And they say, great. Fasting seems like a great way to do it. I'd say,
01:00:54.240
you're absolutely right. And they say, well, how long do I need to fast, Peter?
01:00:57.560
Guess what I get to say? I don't know. And I'll tell you in reality what I say. I say, well, look,
01:01:03.220
I'm really sure that after about seven days of nothing but water, autophagy is fully cranked.
01:01:09.320
And I'm also really sure that if you just go 12 hours without a meal, you probably haven't done
01:01:15.120
anything. Where I struggle is we're between them. Now I want to share with you some personal
01:01:21.100
experience and I want you to weigh in on it. And then I think maybe we can pivot off into
01:01:25.780
actually kind of going back to what you and I spoke about over the phone five or six years ago,
01:01:30.200
which is what would a molecular signature for autophagy look like? And again, I think this is,
01:01:36.340
I put this in the top three most important translational questions in my field. In other words,
01:01:42.380
as I think about the practice of medicine, as it pertains to longevity, it's our inability to
01:01:49.140
understand how to quantify the benefit of nutrient deprivation. In other words, our inability to dose
01:01:55.360
it. That is our greatest, certainly among our top three detriments to using this incredibly potent tool.
01:02:03.280
So I fast a lot. I just finished a fast yesterday, actually. So I used to do a thing where I fasted
01:02:09.080
seven days every quarter. So four times a year, I would just do a water only fast.
01:02:16.960
It is not that hard. I'm going to be completely honest with you. I wish I could sit here and say,
01:02:21.680
oh, I'm a real stud. Nobody can do it. No, no, no. Anybody can do it. I really think anybody can do
01:02:27.060
it. Which is not to say that there aren't moments throughout those fasts where it's sort of difficult,
01:02:31.040
but you'd also be surprised at how resilient the body is. So yeah, not that hard. You have to make
01:02:36.720
some adjustments. Obviously you have to be very thoughtful about how much water you're drinking
01:02:41.020
and how many electrolytes you supplement. There are a lot of changes that are happening in terms
01:02:44.640
of electrolyte management and things like that. But again, we certainly have the knowledge to know
01:02:49.120
how to manage people through that. But I began to ask the question, right? Which is, okay, is seven
01:02:55.180
days a quarter the right dose? I'm convinced that it's a big bolus of autophagy, but is it frequent
01:03:01.400
enough? What about three days every month? That's about the same number of total days fasted,
01:03:08.200
but it's more frequent, but it's probably less potent. And the reason I sort of decided to try
01:03:12.680
three days a month was I noticed that a couple of things happened at the end of my fasts. So I always
01:03:19.500
check my blood before and after one of these seven day fasts, and there's a very predictable set of
01:03:24.260
changes that occurs. Some of them that are really obvious. Glucose plummets. Insulin becomes
01:03:29.260
unmeasurable. Uric acid goes through the roof, along with beta-hydroxybutyrate, of course.
01:03:36.080
Two possible explanations for the uric acid going through the roof. One is the breakdown of nucleic
01:03:41.500
acid. And obviously, when I talk go through, I mean doubling of uric acid. So much so that I
01:03:46.980
started taking allopurinol during a fast to make sure I didn't get gout. Of course, it could also be,
01:03:52.900
and I've read something that says that uric acid and BHB compete for the same transporter in the
01:03:58.340
kidneys. So there might also be a bit of a competitive blockade, but nevertheless, we have
01:04:01.940
at least one possible explanation there. Endocrine function changes dramatically. T3 goes down
01:04:07.380
significantly and reverse T3 goes up significantly such that the ratio of them changes by four to six
01:04:14.720
fold, which means you basically shut off metabolism. Not surprising. Explains why you become incredibly
01:04:21.620
cold and tolerant during a fast. And also gonadotropins go down. So you have all these really
01:04:27.540
predictable things. Well, what I noticed was I see virtually all of them, though not quite to the
01:04:32.620
same magnitude after three days, but not after two days. So that just got me intuitively thinking
01:04:38.680
in a hand-waving way that three days was sort of the minimum dose you needed to really move the
01:04:47.200
needle on a bunch of these other metabolic things, meaning the spike in uric acid, the bottoming out
01:04:52.400
of glucose. So there's another thing that sort of happens. It's as you turn more and more free fatty
01:04:57.460
acid into ketone and turn more glycerol into glucose, you reach an equilibrium where your glucose is
01:05:03.800
pretty much going to stay at about three to four millimolar. And that takes about two to three days.
01:05:09.540
And again, when we think about it through the lens, we've already discussed AMPK must be up through the
01:05:15.560
roof, mTOR must be through the floor, and protein deacetylation must be off. I think my gestalt is
01:05:23.820
that that takes about three days. And obviously it gets greater and greater the more you go. But what
01:05:29.640
would be amazing is if I could draw a tube of blood, send it to you after a three-day fast, a four-day fast,
01:05:36.960
a five-day fast, a seven-day fast, a 10-day fast, and get some sort of quantification. What is it that we
01:05:44.080
would see in... Now, of course, it's complicated because you'd probably want to accompany each of
01:05:49.140
those tubes of blood with a muscle biopsy so that you could look at LC3, LC2, and things like that.
01:05:53.580
So I'll stop on my diatribe for a moment and now turn it over to you, which is where would you even
01:05:59.260
begin to look for that signature of autophagy? And let's just start broadly with any tissue. You can
01:06:03.800
have blood, you can have muscle, you can have liver, you can have adipose tissue. How would you now
01:06:08.900
create a dose effect? Well, we know that what happens in a mouse, let's just take a minute to
01:06:17.020
discuss that. So Mizushima Lab made a mouse that had a transgenic LC3 EGFP protein expressed,
01:06:26.440
and they could use that mouse. Tell folks what LC3 is just so... Because we're going to talk about
01:06:30.340
this quite a bit. So LC3 is the protein that is attached to the autophagosome membrane and links
01:06:38.600
to the cargo that ends up in the autophagosome. So this is a very mechanical thing, right? Like
01:06:44.600
this goes back to your observation in the electron microscope. Exactly right. So LC3 is one of the
01:06:50.920
key proteins attached to the autophagosome membrane. And you use it to see autophagosomes because
01:06:59.960
normally when autophagy is off, LC3 is diffuse. But when autophagosomes form, the LC3 protein is
01:07:10.020
attached to them and you start to see spots where all the autophagosomes are present. And so the
01:07:17.520
Mizushima Lab used that to assess autophagy in a living mouse. They fasted the mouse and they found that
01:07:26.920
they could see the formation of autophagosomes throughout the mouse.
01:07:31.560
And could they do this in like PBMC out of blood or did they need to use tissue?
01:07:35.560
They did it with tissue. What they learned was that yes, autophagy is turned on during fasting in
01:07:41.880
a mouse, which wasn't surprising, but it seemed to not be uniform across every tissue. So that was
01:07:50.000
interesting. But we don't have a way to do that in people. All we can do, because this is involved
01:07:57.420
making a genetically engineered mouse. So the only thing we can do in people would be to look at a
01:08:04.100
tissue section and stain it for LC3 and look to see if there were spots.
01:08:09.700
In other words, you could not look at LC3 conversion in white blood cells.
01:08:14.000
You could, but there's another problem in that you could take PBMCs and do a Western blot for LC3
01:08:21.380
and LC3 gets processed from LC3 one to two. And the two form is the one that's attached to the
01:08:29.660
autophagosome membrane. So you could do a Western blot of PBMCs to measure the conversion of one to two,
01:08:38.980
but then two ends up in the lysosome and gets degraded. So the typical measurement of
01:08:47.280
autophagic flux involves measuring the rate at which LC3 one gets converted to LC3 two,
01:08:55.160
and then the rate at which LC3 two ends up being degraded in the lysosome. And in order to see that
01:09:03.060
flux, you need to block the degradation of LC3 two in the lysosome with baphylomycin or hydroxychloroquine.
01:09:13.080
And so you would only be able by looking at LC3 one and two in PBMCs in a person that was fasting,
01:09:21.460
you would only be able to infer autophagic flux because you wouldn't actually be able to measure it.
01:09:29.360
It's a clue. It's a clue. It wouldn't be proof, but it would be one could presume. I would expect
01:09:36.680
you would see more conversion of one to two and then two going into the lysosome. I don't think
01:09:43.140
that would get you the answer that you need. Now, what if we had a hundred volunteers who are willing
01:09:48.340
to fast and subject to blood draws and muscle biopsies? So you could use the muscle biopsies
01:09:56.100
to actually quantify the flux and establish, let's say you could do it at a different time point.
01:10:01.780
So you had a hundred people fast for different periods of time, three, four, five, six, seven
01:10:06.080
days, et cetera. You've got tissue and you've got blood. What else could you look for? So again,
01:10:11.620
could BHB be a proxy? Could glucose be a proxy? I remember you once mentioning another organic
01:10:18.600
molecule you had identified. You knew it by how many carbons it had, and you thought it was ringed,
01:10:24.360
but you weren't sure what it was yet. Have you figured that out?
01:10:27.540
Yes. That was something that accumulated when we inhibited autophagy, and that was glucuronic acid.
01:10:34.560
So that would be, I think you're going down the right road. So I think what we can do,
01:10:41.720
and we haven't really done this yet, would be to look at metabolites because metabolism is so
01:10:50.300
drastically changed. So if we can't look at directly measure autophagic flux in humans very easily,
01:10:57.860
because we don't yet have the proper tools, we could use metabolites as surrogate markers for
01:11:11.940
That's exactly why I call it a signature as opposed to a biomarker, because I think it's basically,
01:11:17.440
how do you use machine learning to take many metabolites? There's a bunch of things we know
01:11:23.820
are happening. We just have to integrate them. We know that leucine is going down. We know
01:11:27.960
methionine will be almost unmeasurable. We know what's going to happen to glucose, uric acid. And
01:11:33.400
then there's probably a whole bunch of other small molecules and things in the proteome that we don't
01:11:37.500
yet know that are probably discernible from PBMC directly or indirectly through other things in
01:11:44.620
the plasma. And it just seems like a problem that is so ripe for a machine learning environment where
01:11:51.000
you don't need that many people because you know what the gold standard is. You just starve them. And
01:11:56.820
then you have the check, which is the muscle biopsy, which can give you some sort of quantifiable
01:12:01.140
gradation. I mean, do you get the sense that that's something an IRB would approve? It's invasive,
01:12:06.500
you know, it requires biopsies and fasting and things like that. But, or would they demand that you,
01:12:10.540
hey, first you have to do this in mice? That's what I would expect. And so one of the things that
01:12:15.840
we have been talking about is we've done some of this, but probably not enough, is to do a metabolic
01:12:24.600
characterization of a wild type mouse fasted versus an autophagy deficient mouse fasted. I think that
01:12:33.460
would potentially identify the metabolic changes that were autophagy dependent. And I think that would
01:12:40.520
provide some clues as to what to look at in humans, because the problem with looking at metabolism
01:12:47.680
is you get an enormous amount of data and it's very, very helpful to know what to look for. We may
01:12:54.520
have a list of things that are obvious to look for, but... Right, but the fine tuning is going to come
01:12:59.660
in the non-obvious. It's not going to be a regression model based on five things we know. It's going to be
01:13:04.720
much more complicated. And I prefer not the under the lamppost science.
01:13:10.780
Yeah, take an unbiased view and go... And honestly, I get asked about this more than any other
01:13:17.240
translational problem. So the good news is I think there are a lot of people in the philanthropic
01:13:22.180
community that would be interested in this, even if this is not a question NIH is interested in.
01:13:26.880
I doubt NIH is interested in this problem, although that strikes me as
01:13:30.760
odd given how potent a tool fasting is and yet how we don't know how to dose it. And I think it's worth
01:13:37.280
pausing on that for a moment because that is such a stark statement, if I'm correct. I believe I am.
01:13:43.160
Which is, imagine we had the most amazing drug imaginable. Imagine we had a proteose inhibitor
01:13:50.640
for HIV and we knew deep down this could cure HIV. The problem is we didn't know how to dose it.
01:13:56.580
How long would we tolerate that ignorance? Imagine we had a drug that we knew could kill cancer,
01:14:04.260
but we just didn't know how much to give or how often to give it. We wouldn't tolerate that for
01:14:09.240
a minute. And yet in fasting, we have arguably the most potent tool, and certainly if not the most
01:14:17.600
potent, probably one of the three most potent tools in which we can affect human health. And we don't have
01:14:23.900
a clue how to dose it or what frequency with which to use it. And I find that ridiculous.
01:14:31.180
So I'm actually really confident that if there were a really great proposal put together that
01:14:38.380
would go from the animal model to the human model, it would be fundable. It would be fully fundable
01:14:44.140
through philanthropic efforts. And so if nothing else comes of this discussion, I would love to plant
01:14:49.300
that seed with you and think about what would be the right consortium of people to do that work.
01:14:54.380
Obviously, there are lots of skill sets that we'd want to have involved in there, but I really believe
01:14:59.640
that could be funded quite easily. And I think that the implication of that is as potent as anything
01:15:04.400
else. Because again, here I am doing my three-day fast every month versus my seven-day every quarter
01:15:09.840
versus five-day every quarter. We just don't know. And it really is troubling to me. It just drives me insane.
01:15:16.400
Well, I think for the general community, I think it's an important question, even for practical
01:15:23.360
reasons, because you may be able to control your life to the extent that you can do all this at your
01:15:32.720
own convenience. But a lot of people don't have that flexibility. And so if they can be told that
01:15:40.820
fasting for X amount of time is all you need to do, then the beneficial effects of fasting could be,
01:15:49.560
there would be more people that could take advantage of it.
01:15:52.500
Absolutely. And if you look at the work of someone like Walter Longo, who his assertion is,
01:15:58.300
you can get most of the benefit without actually having to be fully fasted, but to do something that
01:16:03.260
is like a fast mimic, where you reduce your calories significantly for a period of five days.
01:16:08.260
Again, maybe he's right, but we have no idea. We have no idea what the efficacy of that approach
01:16:15.120
is versus a total water-only fast for five days. And it would be great to know, because
01:16:20.040
if we could demonstrate that you're getting 80% of the benefit doing a fast mimicking diet versus a
01:16:25.740
complete fast, well, that opens the door to many more people who would be willing to do fast mimicry
01:16:31.400
versus an outright fast. And again, I think about this constantly, which is, I'm almost willing to
01:16:37.980
do anything. I just want to know what to do. So I think that now is the right time to ask that
01:16:44.000
question. Let me just digress a little bit to talk about metabolism. So we know a lot about metabolism,
01:16:52.660
essentially the field of not only just cancer metabolism, but metabolism in general mapped out
01:16:59.640
all the metabolic, most of the metabolic pathways. But what we lack the ability to do until fairly
01:17:07.000
recently was to have a thorough understanding of metabolism in a living mammal. And so Joshua
01:17:14.920
Binowitz and I have invested a lot of effort in developing technology to use isotope tracers.
01:17:23.800
This would be C13 labeled glucose and amino acids and so forth. And to deliver them to living mice
01:17:32.880
running around and doing normal mice things in a cage, and then look to see how they're used and how
01:17:40.160
different tissues use them and how there's nutrients sharing between tissues. Because when you're
01:17:47.460
fasting, there's many complicated things going on. It's not just like there's no food and you're
01:17:54.880
inducing autophagy and that's that. That's the only thing that's happening in a vacuum, right?
01:17:59.500
So you have dedicated nutrient stores, you have glycogen in your liver that's mobilized,
01:18:04.620
and that's dumping glucose into the bloodstream. You have made out of post tissue that starts
01:18:11.300
degrading your triglycerides, and then you end up with glycerol and fatty acids in the bloodstream,
01:18:17.640
which then, you know, are taken up by the liver and so forth. So you have all these, you know, if you're
01:18:23.580
really without nutrients for a long time, then your muscle proteins start being degraded, which is
01:18:30.120
probably undesirable. That's dumping amino acids into the circulation so that you can maintain your
01:18:36.920
survival. We have to understand all of that. Because it really occurs in different phases.
01:18:43.320
Again, if we just limit it to humans for a moment where we have a pretty good understanding of this,
01:18:48.000
what's happening in the first 24 hours versus the next 24 hours versus the next 24 hours is very
01:18:53.060
different. And George Cahill's famous fasting study, the 40-day fast on the healthy subjects,
01:18:58.400
really divides it into these phases. What's interesting is by about seven days into a
01:19:05.220
prolonged fast, you pretty much reach a steady state. You've got a pretty consistent flux of
01:19:10.900
triglyceride into free fatty acid out of the fat cell. You reach a steady state level of beta
01:19:16.120
hydroxybutyrate, acetoacetate, and glucose, such that basically the sum total of them in millimolar
01:19:22.160
concentrations is about preserved to where you would be non-fasting-like. And so it begs the question,
01:19:28.660
if we posit that once you reach that steady state of seven to 10 days, you're clearly in a fully
01:19:34.680
turned on autophagy state, what's the switch look like? When you're 24 hours or 48 hours or 72 hours
01:19:42.720
into that, are you 80% of the way to the benefit or just 20%? That's a jugular question.
01:19:48.720
Yes. I think it would be fascinating to understand that. And I think that if you look back over
01:19:56.160
history, almost all cultures have fasting as part of their history. And I'm thinking that
01:20:05.080
that is not by accident. I think they must have learned by trial and error that this was a healthy
01:20:11.580
thing to do. And so I think that autophagy, I would expect is playing a major role in promoting health
01:20:20.340
in response to fasting. But I really think, well, maybe I'm sticking my neck out, but I think
01:20:26.440
using fasting as opposed to trying to find some pill you could take is something that's easy to do.
01:20:34.840
And of course, it speaks to the irony of it, which is if you took probably 1% of the budget that is being
01:20:40.900
dispensed to find pills that stimulate autophagy, we would actually be able to answer this question
01:20:46.240
clearly and actually just have a dose of response. And look, that doesn't mean these things can't
01:20:51.680
coexist. I'm all for it. And I wanted to ask you, of course, about some of the other pills like
01:20:57.320
rapamycin and metformin and the role that they might have and how we might be able to measure that.
01:21:00.800
But again, this just strikes me as the most obvious question in the space of how to prevent disease.
01:21:09.580
And it's like you have this beautiful, beautiful tool and you don't know what the dose is and you
01:21:16.800
don't know what the frequency is. If someone knows that they're susceptible to a neurodegenerative disease,
01:21:23.740
has anyone looked at those people to see if they engaged in some sort of fasting regimen,
01:21:31.800
whether that was helpful or not? Indirectly. I mean, it's possible that that's been done
01:21:37.040
directly and I just am not familiar with that. I think what we've seen indirectly is dietary
01:21:42.260
restriction as opposed to just pure caloric restriction where you improve the quality of
01:21:47.680
macronutrients, specifically around improving glycemic control. You can take people that are in an
01:21:53.680
early stage of cognitive impairment and delay it and or reverse it through that type of nutritional
01:21:59.260
intervention. Now, of course, that doesn't necessarily say autophagy is playing a role
01:22:03.640
because that's doing a lot of other things. It's improving glucose and insulin signaling in the
01:22:09.460
brain. It's doing a lot of other things and we're really starting to see the impact of metabolism in
01:22:14.000
the brain. So that's not entirely clear. Indirectly, I would say there are, I think, some pretty
01:22:20.200
interesting, compelling pilot data that suggests that rapamycin is neuroprotective. And again,
01:22:27.180
rapamycin, a very potent inhibitor of mTOR, would presumably on some level induce autophagy. I think
01:22:33.320
it's a very interesting question as to what is it about rapamycin that induces a longevity phenotype.
01:22:41.600
Rapamycin to me is the most interesting molecule out there because it is, I think, the only molecule
01:22:46.720
that has demonstrated a longevity benefit across all four models of eukaryotic cells. So that's a
01:22:53.860
really big deal that can't be ignored. But how much of that benefit is through autophagy? I'd like to
01:22:59.160
turn that question to you. How much of it is through inhibition of senescent cells, reduction of
01:23:04.940
inflammation? Again, so it's very indirect and it speaks to, again, I don't mean to sound like a
01:23:11.380
conspiracy theory guy because I'm not, but it is a little frustrating that we have these amazing
01:23:16.300
tools, but because they're not particularly profitable, you don't really have somebody
01:23:20.180
that's interested in answering them. And that's why I, again, come back to, A, I think these are
01:23:24.380
answerable questions. B, I don't think they are billion dollar questions. I think they are really
01:23:29.200
questions that are amenable to the philanthropic community. And I think from an ROI perspective,
01:23:34.920
it's hard to think of examples of where you could put dollars to work in research that would
01:23:41.380
Right. And I think that our biomedical community is mostly focused on putting out fires rather than
01:23:50.980
disease prevention, although I've seen a change. I mean, I see at the NCI, the National Cancer
01:23:56.960
Institute, a bigger interest in cancer prevention. So I think people are coming around to realizing that
01:24:05.980
making people healthier longer is probably more important than once they discover to have stage
01:24:13.660
four pancreatic cancer, what can we throw at it to make them live another two months?
01:24:20.620
Yeah. Again, it is sort of amazing to me how lopsided our resource allocation is with respect to that
01:24:28.500
problem, because you're absolutely right. We have spent probably a quarter of a trillion dollars
01:24:34.960
in the last 40 years on the second question, which is once you have metastatic cancer, how do you live
01:24:42.360
longer? And we've done an analysis on this. So for the quarter of a trillion dollars that has been spent
01:24:48.080
on that problem on average for solid organ tumors, we have extended median survival by less than about
01:24:55.900
a year since 1970. So almost 50 years. That's pretty sad when you think about the fact that there's not
01:25:03.500
much evidence we've reduced the arrival of cancer. In fact, all we've done is basically come up with a
01:25:10.700
second leading cause of cancer in terms of modifiable behavior, which is after smoking. It
01:25:16.060
becomes down to diabetes, insulin resistance, and all of the metabolic dysregulation. So yeah, I'll get
01:25:22.080
off my soapbox now. But again, this is in many ways just a sort of a plea for help, which is I think
01:25:27.700
there's an amazing opportunity to understand this. So there's another component to this that worries me
01:25:33.980
greatly. So what we've seen, you know, so a lot of this, you're talking about controlling metabolism
01:25:42.400
to preserve health through implementation of fasting and understanding fasting. But look what's
01:25:49.740
happened to the American diet. I mean, there are people now that don't even recognize vegetables in
01:25:59.480
the supermarket. There are people that only eat prepared food. And so what we've seen is, on the
01:26:09.200
one hand, you're talking about preserving health and all that. But on the other hand, the overall
01:26:14.840
health of Americans is deteriorating. Obesity is greatly increased and has no sign of abating.
01:26:23.180
The diet of Americans loaded with high fructose corn syrup and diets that are disproportionate with
01:26:32.360
prepared food. So the only way to globally improve the health of Americans or anyone else for that
01:26:41.040
matter is to deal with both of these problems at the same time. And to me, that's probably the
01:26:46.880
greatest line of reasoning that says fasting is probably protective against all chronic disease.
01:26:53.900
Because if you look at the three main chronic diseases that account for, to our last analysis, 82%
01:27:01.660
of deaths above the age of 50 in the United States, excluding COPD. So if you take out the obvious
01:27:08.880
smoking-related death of COPD, 82% of death is attributable to cardiovascular disease, cancer,
01:27:15.540
Alzheimer's disease, and complications of diabetes. That's pretty stark. There's no question that when
01:27:23.980
you improve metabolic health, which you can do through fasting, you reduce the risk of all of
01:27:29.420
those significantly. Of course, the question becomes, how much of a role does autophagy play in
01:27:34.900
that? Specifically, you look at the example you gave of neurodegeneration. That makes a very compelling
01:27:39.920
case for it. Probably also in cancer. What do we know about cardiovascular disease, by the way?
01:27:44.540
Nothing comes to mind. I don't recall seeing anything in that area.
01:27:50.600
Yeah. I mean, my take on the literature is that the benefits of fasting in cardiovascular disease
01:27:58.060
are primarily mediated through the metabolic health benefits of it. Lower glucose, lower insulin,
01:28:04.880
lower homocysteine in time, lower inflammation primarily, as opposed to something that directly
01:28:11.480
pertains to ApoB or the inflammatory response to that. But again, maybe it's just there and I
01:28:17.620
haven't seen it. What else do you think is going on? What travels with autophagy? Can we talk about
01:28:22.700
senescence for a moment? Do we understand a sense of what's happening when an animal or a human is
01:28:27.240
undergoing autophagy with respect to either SASP or just the overall senescent cells?
01:28:33.660
Yeah. There seems to be complicated roles for autophagy and senescence. There's evidence from
01:28:41.780
the Noreta lab that SASP, the secretion of inflammatory factors that occurs during senescence
01:28:49.360
is facilitated by autophagy. But then in the cancer setting, there's also examples where
01:28:57.680
loss of autophagy limits senescence. So I think in the senescence area, it's still a little bit
01:29:05.320
confusing and maybe a little bit context dependent as to what's happening.
01:29:11.640
And then going back to the question about molecules, what do we know about metformin
01:29:16.360
and autophagy? Do we know that in a fed state, if we give an animal or a human metformin,
01:29:23.580
we can still induce autophagy, all things equal through just the AMPK activation?
01:29:28.820
Yes. And I think that that's true, but I think that we don't understand over the long term what
01:29:35.880
happens and what the consequence of having autophagy or not having autophagy is. So for example,
01:29:43.640
we've never given metformin to our mice that don't have autophagy. That might be an interesting
01:29:49.920
thing to do. What is the consequence of autophagy induction by metformin? It actually might be
01:29:57.520
better to do that in a system where autophagy could be, wasn't completely gone, but could be
01:30:05.940
toggled up. Do you have the ability to turn autophagy into an analog versus a digital,
01:30:12.760
meaning where you can actually use gradations versus just on or off?
01:30:17.120
Yes. I think the mouse model where autophagy, the expression of a central autophagy gene is
01:30:24.320
controlled by an shRNA might be the way to do that experiment.
01:30:29.000
And then what about rapamycin? What do we know about the use of rapamycin, which has been studied
01:30:36.040
so liberally across, again, everything from yeast, flies, worms, mammals, uniformly extends life,
01:30:42.680
potent inhibitor of mTOR, which would signal autophagy, all things equal. Where do we see
01:30:47.600
that relationship? So there's been a lot of discussion about using rapamycin or rapalogs
01:30:54.340
as autophagy stimulators, but it's like what you said before, it does many other things and
01:31:03.880
Although that also depends on the dose, right? I mean, the Evrolimus data suggested that it was
01:31:09.020
actually immune enhancing when given intermittently.
01:31:12.300
I also have to remember that if you have a small molecule like rapamycin and you want to
01:31:18.480
use it to preserve someone's health, you have to make sure that it's safe. And I think that's when
01:31:26.360
everyone backs away. Because if you've got cancer and they want to try an experimental drug and you've
01:31:33.560
got no other hope and you're going to be dead in a short period of time, there's a bit of latitude in
01:31:41.240
what can be done clinically to test whether or not there's a small molecule or some sort of drug that
01:31:48.340
will be safe and possibly have efficacy. But when you're talking about prevention, it's a big problem.
01:31:57.520
The drug companies are not interested in it because the amount of time it would take in the risk of...
01:32:05.060
Right. Just a much narrower margin. By the way, that's exactly the reason we're in the situation
01:32:09.260
we're in. So just to reiterate, we have a situation where I am not convinced that longevity as a game
01:32:17.280
is going to be one on the back of extending the time you have a disease. I have never seen a shred
01:32:23.880
of evidence to suggest that that is the answer. Everything in humans and animals points to the
01:32:29.760
opposite end of the spectrum. Longevity is about delaying the time it takes until disease comes.
01:32:35.420
The implication of that is prevention is the single most important tool in the longevity toolkit.
01:32:41.220
How do we reconcile that with what you just said? All of our pharmacologic efforts,
01:32:46.140
the trillion dollars we spend on drug development is all on the wrong side of the equation.
01:32:53.200
It's on the how do you live longer once you have a disease? And I understand why that's the case
01:32:59.900
for all the reasons you just said. And if that doesn't make the most compelling case for taking
01:33:05.520
the best and safest drug of them all, which is fasting and understanding how to dose it and what
01:33:11.000
frequency to dose it, I don't know what makes a better case. Along with exercise, by the way,
01:33:14.820
I put exercise in that same category, which is it bothers me that we don't really know how to dose
01:33:20.140
exercise either. I mean, it's less of a problem, I think, because for most people, the issue is do
01:33:26.480
more, but it would be really nice to know what the dose response is on different types of exercise,
01:33:33.340
especially for people who want to do the minimum effective amount. So both from an exercise
01:33:37.840
perspective and a nutrient deprivation perspective, there's no more low hanging fruit
01:33:42.760
in terms of minimizing human suffering than understanding how these things work.
01:33:49.980
David Sabatini and I have talked about this at length, and he has constantly told me to do this.
01:33:55.420
And the way we've thought about it, it's not going to happen because I won't do it.
01:34:00.720
The way David describes it very eloquently is, right now, metabolic response to nutrients is
01:34:07.260
a black box. And what David thinks, and I think he's right, is there's a multi-billion dollar
01:34:13.440
opportunity in decoding the black box. In other words, when we understand exactly what the response
01:34:20.640
is to each different type of nutrient in every different dose and frequency, and we can decode that
01:34:26.540
in the way that we can do with so many other biochemical processes, you can do everything.
01:34:31.220
Because then you could actually develop drugs, probably, that could actually do something.
01:34:34.500
So there's a drug development platform that comes out of that. And then from my standpoint,
01:34:38.480
what I'm really interested in is simply just on the front lines as a sort of knuckle-dragging doctor,
01:34:43.820
how do you even just put this into clinical practice? But again, it's high risk. It's a lot of
01:34:48.900
effort to do part of that. I think on the drug development side, there's a lot there. I don't think
01:34:53.060
it's very high risk on the question I posed to you earlier. I think let's do the mouse study
01:34:58.860
and identify the 50 metabolites, proteomic signature things that are generally going up
01:35:07.180
with autophagy, and then let's shotgun that in an unbiased way against human subjects. I feel like
01:35:13.200
that's a project in the tens of millions of dollars, not even the hundreds of millions of dollars.
01:35:18.840
And again, if you add one year of life to each human as a result of that, that's kind of staggering.
01:35:25.420
Right. And I think if you couple understanding mechanisms of metabolic delay of damaging diseases
01:35:35.600
with surveillance for risk factors, I think those two things really need to be coupled together
01:35:44.080
because you can, even if you define what the optimal diet and exercise and fasting regimen is for
01:35:53.940
delaying the onset of disease, there are still unlucky people. And I think that we can't forget about
01:36:02.780
them in the context of health and longevity and well-being because you could have the healthiest diet
01:36:09.740
and do everything right. Vogelstein has written about this, right? I mean, there's clearly a
01:36:14.660
component, there's a stochastic component to this. And yeah, so absolutely. And again, I don't think
01:36:19.720
there's any reason to believe that we couldn't be addressing both of these.
01:36:22.500
Yes. I mean, I think that there's no reason to do everything. One always has to bear in mind that
01:36:28.960
there is this other risk factor that no matter what happens with understanding metabolism and fasting and
01:36:37.520
good health practices, that other thing is still going to be there. If you have a BRCA1 mutation,
01:36:48.300
So in 2016, the Nobel Prize was awarded for basically the genetic elucidation of autophagy.
01:36:55.500
What are the salient features of that award? What was it about Osumi's work that led to that award?
01:37:00.940
So what Osumi did was quite profound and very creative. He developed an assay. Well, he asked,
01:37:08.920
what are the, I mean, yeast requires nitrogen for survival. And he asked, what are the genes that
01:37:15.040
are required for nitrogen survival? And he identified the autophagy, essential autophagy genes.
01:37:21.780
And I always wondered whether if he was in the United States, would work like that be funded?
01:37:29.580
Because it just seems like it was an important question, but-
01:37:33.860
It didn't have such a clear application down the line.
01:37:40.060
Right. And also the clear disease connection wasn't there and so forth and so on. And nonetheless,
01:37:46.220
he did that. And I guess the point is, is that sometimes scientific discoveries are so basic
01:37:53.280
that you can't ever anticipate what it would ultimately lead to. And in this case, it led to
01:38:00.740
something very extraordinary, but he probably had no idea at the time. And once they discovered these
01:38:09.120
essential autophagy genes in yeast, then it was apparent that there were homologs in mammals and so
01:38:16.220
How conserved are those genes between yeast and mammals?
01:38:19.600
If you do a blast search, you can see them. I mean, not all of them, but the amino acid homology
01:38:29.220
Wow. So when you sort of think about the future of this, I think so much of what we've talked about
01:38:35.060
kind of feeds into what your optimism is, but how do you want to spend the next 10 years of your
01:38:41.160
career? What are the questions you want to probe?
01:38:43.900
I think I would like to translate what we've learned about the role of autophagy in cancer.
01:38:52.720
And that involves developing small molecule inhibitors to inhibit autophagy for cancer therapy.
01:39:01.740
And Alec Kiliman and I started a company to do that. And what we're focusing on now is defining at the
01:39:12.080
molecular level what the functional requirements for autophagy are in individual cancers. And this
01:39:21.340
involves understanding the metabolic role of autophagy, why one cancer needs autophagy more than another.
01:39:28.160
And then the newest connection is the connection to inflammation. When you inactivate autophagy,
01:39:34.920
you stimulate inflammation. And this is what we've talked about earlier. In the context of cancer,
01:39:40.720
that could be a really good thing because the game changer in cancer therapy now is immune checkpoint
01:39:48.160
blockade. In fact, what I was just talking about at the ACR meeting yesterday was the particular
01:39:55.860
patient that came to our cancer center and went through surgery, radiation, chemotherapy,
01:40:03.620
and it all failed. And her body was riddled with tumors. And she went on a clinical trial
01:40:11.540
for immune checkpoint blockade and all the tumors melted away. And that was five years ago. And she's
01:40:18.120
perfectly fine. So what we have to do is make that work for everybody. And if inhibiting autophagy activates
01:40:26.820
the immune response and can facilitate not people who wouldn't respond to immune checkpoint blockade
01:40:34.200
to respond, then that would be critically important to do.
01:40:39.560
I mean, let me think about that for a second. So when we think about the patients that are responsive,
01:40:45.220
and we really have two big targets, right? CTLA-4 and PD-1. Melanoma obviously is a huge
01:40:53.580
success story here because it is so mutagenic. It's interesting. I have a friend who has Lynch
01:40:59.820
syndrome. So that's a familial syndrome where people are predisposed to cancer. He developed
01:41:05.580
colon cancer when he was quite young, went on to develop pancreatic cancer, adenocarcinoma of the
01:41:10.560
pancreas, which is uniformly fatal, almost without exception. He presented with an advanced state.
01:41:16.340
So he was not even a surgical candidate. So the tumor had completely engulfed his mesenteric artery
01:41:21.760
and vein, which meant he couldn't even undergo the surgical procedure, though it wouldn't have done
01:41:26.480
much anyway. I had just read a paper six months earlier in the New England Journal of Medicine
01:41:32.420
about, I forget what the paper was exactly about, but it made me think that because he had Lynch
01:41:40.080
syndrome and he has so many mutations, he might be a candidate for a checkpoint inhibitor.
01:41:45.000
So we went back to his oncologist and said, hey, can we get him on Keytruda? They said,
01:41:49.860
which is an anti-PD-1. They said, no, there's no standard for that. But we found a clinical trial,
01:41:56.600
actually got him in. He got Keytruda. That was five years ago. He's disease-free. So you go from
01:42:03.580
unresectable pancreatic adenocarcinoma to no pancreatic cancer. Pretty remarkable.
01:42:09.720
Now the question is, when I think about how broadly extendable that's going to be,
01:42:15.780
it really comes down to how many shots on gold do you get? How many mutations do you get
01:42:21.220
such that you can activate these checkpoint inhibitors? And so tell me how autophagy fits
01:42:27.500
into that, because I think I'm missing the link of why enhanced immune, non-specific immune response
01:42:35.160
would factor into that. I know there's a link, but I need you to explain it to me.
01:42:39.400
So that's exactly where we're going with our research.
01:42:45.940
So we know that tumors with a very high mutation burden respond better to immune checkpoint blockade.
01:42:54.480
But it's not that simple, because there are patients with tumors that do have a high mutation
01:42:59.300
burden that don't respond, and we don't know why. It could be they've upregulated some other
01:43:04.820
checkpoint that we can't yet inhibit, or it could be some other reason they don't express class one,
01:43:10.720
or that the immune system can't see the tumor for some various reasons. And then we also know
01:43:17.340
there are tumors that have a low mutation burden that do respond.
01:43:20.800
Yeah. And so a big part, in fact, we just got an NIH grant to study this, is to make mouse models
01:43:30.020
of cancer with low, medium, and high mutation burden with which to study.
01:43:38.740
Exactly. We haven't done the autophagy part yet. We're just generating the models using proofreading
01:43:46.440
mutations and polymerase epsilon and delta to generate mice with cancer with various levels
01:43:55.200
of mutation burden in their tumors. And this is so cool, because we'll be able to ask basic
01:44:01.800
questions like, how many mutations do you need? When you have a low mutation burden, what can you do
01:44:08.020
to make the immune system see that tumor? Do you need only mutations in the nuclear genome? What about
01:44:15.680
mutations in the mitochondrial genome? So one of the mouse models we made was to generate a mutator
01:44:23.700
phenotype in the mitochondrial genome. There are human cancers that have a high level of mitochondrial
01:44:30.500
genome mutations. Whether that has any effect on anything is completely unknown. There's no reason why
01:44:41.860
And you'd think, if anything, they would be more immunogenic. I mean, they should be, all things equal,
01:44:47.600
just because of their bacterial origin. That should elicit a much greater immune response.
01:44:52.000
Exactly right. This is what this grant is designed to do, to generate mutator phenotypes
01:44:57.820
in mouse models of cancer, so we can have a spectrum from low to really high mutations
01:45:03.780
in the nuclear genome as well as the mitochondrial genome, then to figure out the mechanism of response
01:45:09.960
to immune checkpoint blockade to make cold tumors hot. And that's essentially what the loss of
01:45:17.640
autophagy is doing by promoting inflammation. It's taking a tumor that is not killed by T-cells,
01:45:24.920
that does not respond to immune checkpoint blockade, and rendering that tumor responsive.
01:45:30.540
And where do you put this in the hierarchy of optimism for the future of cancer therapy? I mean,
01:45:37.480
to me, the interesting stuff in cancer therapy is getting more and more targeted and stacking more
01:45:41.860
and more therapies on top of each other. So this is an elegant example of stacking something that is
01:45:47.780
clearly going to become a pillar of oncology, which is immune-based therapy, with something that,
01:45:53.980
frankly, is partially metabolic and, frankly, partially more complicated than just metabolic therapy.
01:45:59.920
So you've got, you almost add this to the layer of pieces of Swiss cheese you start to stack on top.
01:46:06.200
If you have enough of them, you're not going to be able to drop a pencil through. The cancer doesn't
01:46:09.240
survive. That's right. So one of the limitations that we have with immune checkpoint blockade is,
01:46:16.100
some of which I've already mentioned, we can't identify who's going to respond and who's not going
01:46:21.480
to respond, and we have to extend the responder pool. But we have to be able to model that,
01:46:28.800
because it's very clear that as single agents, there's going to be immune checkpoint blockade
01:46:34.540
therapy is not going to help most of the patients. So how do we go about optimizing this treatment?
01:46:43.400
And having models where you can combine immune checkpoint blockade with other therapies to
01:46:51.740
evaluate what is the optimal response is critical, and that's what we're doing. And whether fasting
01:47:03.560
What's the role of autophagy in the immune cell itself? So either adaptive or innate? I mean, maybe both.
01:47:09.740
So we know that one of the things we did was to turn autophagy off in a mouse and ask how that affected
01:47:21.760
basic immune responses. And the answer was, everything in the short term appeared to be
01:47:28.940
completely functional. And if anything, the T cells were more anti-tumorogenic. But if you go into
01:47:37.760
the long term, if you knock out an essential autophagy gene, only in T cells, for example,
01:47:44.740
and look nine months later, I think those T cells are not going to be very functional.
01:47:49.740
But it really depends on how you design the experiment. For cancer therapy, we want to know
01:47:56.620
what happens acutely. When you're inhibiting autophagy, you're going to be looking at things in the
01:48:04.740
short term, not in the long term. So there's still a lot we need to do in that area. But in the short
01:48:13.180
term, for cancer therapy, the immune system seems to function well, if not better, in the presence of
01:48:23.340
And this just doesn't stop getting confusing. Because again, you would think that given the
01:48:31.540
benefits of autophagy and preventing cancer, one of them, you would think that that would only enhance
01:48:38.720
innate immunity because of the role innate immunity plays in cancer screening. Which again, I think just
01:48:44.740
speaks to we are still really scratching the surface of all of the different tentacles that come out of
01:48:54.320
these tools. Something like fasting seems very simple. And it's simple, of course, to do. But it
01:49:00.680
has such a set of pleiotropic extensions and benefits that it's very unlikely that it's about
01:49:08.520
all or none. There's nothing black and white here. It's really all these shades of gray
01:49:13.060
that it's not intuitive when you look at them what the net effect is, because it's a little bit of
01:49:18.640
this, a little bit of that, more of this than that. It's the balance of this versus that.
01:49:23.480
Yes, I would agree. And I think context is important too.
01:49:27.520
When you think of all the big chronic diseases, just based on what you've talked with us today
01:49:31.980
about, I think we have to be really excited about Alzheimer's disease based on the model you've
01:49:36.460
shared. I mean, that strikes me as an amazing opportunity because one, we don't have a single
01:49:43.400
tool. Once somebody has Alzheimer's disease, I'm sure you saw the most recent, I don't know if you
01:49:48.440
follow that literature, but we just saw two enormous failures in the anti-mammeloid beta drug trials.
01:49:56.040
So we're back to kind of square one, which is not a single drug that works for this condition.
01:50:00.380
If any disease demands prevention, it has to be this one. It's hard to make the case that fasting
01:50:08.540
isn't going to play a beneficial role there, isn't it? I believe you. I'd love to-
01:50:13.000
I mean, we have to test this now. Yeah, we have to test. It has to be tested. But I think that when
01:50:17.000
you look at the dramatic failures in preventing or delaying Alzheimer's disease, you have to ask the
01:50:25.720
question, what is the root cause of that? And if you look at the approaches, all the approaches are designed
01:50:33.840
to ameliorate a symptom. And the research has not yet gotten to the root cause. And I think that that is the
01:50:45.680
reason for these spectacular failures, is they're trying to treat a symptom of the disease, rather than the cause of
01:50:55.640
the disease. And when you look at the genes that are involved in neurodegeneration in general,
01:51:03.240
they fall into a broad array of different categories. And so my thinking is that they're all
01:51:10.600
doing different things, but there's some common denominator that has yet to be identified.
01:51:16.220
And I think that until the root cause of disease is identified, just finding means to ameliorate the
01:51:28.440
symptoms is not going to be productive. Eileen, you know, I could sit here and talk about this for
01:51:33.780
hours and hours. I want to be respectful of your time, because I know you've stayed an extra day to
01:51:38.060
have this discussion with me, which I really appreciate. Is there anything else you want to talk
01:51:41.720
about today, either as it pertains to your work, something you're excited about in the future,
01:51:47.060
or anything else that pertains to autophagy? I mean, I think that understanding in greater detail
01:51:54.460
how autophagy impacts metabolism, we've done some of that, but I think there's way more to do.
01:52:02.060
We have the technical ability to examine metabolic flux in a mouse in vivo, in normal, in starvation
01:52:11.260
conditions, and in response to different diseases. And we're only at the beginning of doing that.
01:52:18.400
And I think that that's something that we will continue to do, and hope that we can identify
01:52:25.060
new targets for anti-cancer therapy or signatures of metabolic problems. And we will continue to do
01:52:35.860
that. But again, I want to return to the immunotherapy. I think in the field of cancer,
01:52:41.600
building on that huge gain, we can't take our eyes off that ball.
01:52:48.760
Those are both very interesting. And of course, the former, it sounds like you really agree with
01:52:52.620
David Sabatini, which is there's an enormous opportunity to decode metabolism in a way that
01:52:59.020
we should have done 20 years ago. I think we lack the technology. I mean, I think that,
01:53:04.780
so maybe I could take a minute to explain what we do. And that by using C13 or N15 labeled tracers,
01:53:15.080
you can put them into a mouse, infuse a mouse with these tracers. And by looking at where they go by
01:53:27.060
Over different time points. You can see metabolism. And that was something that was never possible
01:53:34.360
What is it, because we've been able to label these things forever, what, was it the mass spec didn't
01:53:38.740
have the resolution before? Or what is it that, why is it we couldn't do this 20 years ago, I guess?
01:53:42.620
I think they could do it with radioactive material, and they could do it somewhat with
01:53:47.820
the technology they had way back when. But I think that the technology now is far more sophisticated.
01:53:55.200
By using heavy isotopes, you don't need radioactivity. Now there are more mouse models of disease. You
01:54:01.680
could even do this in humans. So Ralph D. Berardinas at UT Southwestern is infusing these isotope
01:54:10.200
tracers into humans with cancer and actually measuring the metabolism of human tumors.
01:54:17.400
Wow. That's interesting. I did an experiment once on myself with doubly labeled water, which of course
01:54:22.000
is a very simple version of doing that sort of thing to examine energy expenditure. I had a field
01:54:28.500
Wow. Yeah. But I think that, in fact, next week I'm supposed to go to a Keystone Tumor Metabolism
01:54:35.600
meeting where all the experts in this area will get together and talk about this in detail. But this
01:54:42.060
is a growing field. It's very exciting, and understanding metabolism in mammals at a level
01:54:52.120
we've never seen before in various disease states is tremendous.
01:54:56.900
And then lastly, is it safe to say that should there be a strong enough public demand and a
01:55:02.720
philanthropic demand to go after that question we talked about earlier about sort of decoding
01:55:08.620
the dose effect of fasting? Is that the sort of thing you'd be interested in working on?
01:55:13.100
Yes. I was fascinated by what happened when mice didn't have autophagy and they died when they
01:55:20.360
were fasted. And I am very much interested in fasting as a way to preserve health. I'm also
01:55:28.940
interested in, as I mentioned earlier, the dietary part, because I think all of this has
01:55:34.260
to go together. It's not just how many calories you eat or how often you eat them. It's what
01:55:40.020
they are. So yes, that's something that's very important to me.
01:55:45.020
Well, Eileen, thank you very much. This was super, super interesting. And I know that folks are
01:55:49.660
going to, this will probably pose a few more questions than, than even we had time to go
01:55:54.220
into, but that's great. Your work is fantastic and I appreciate your generosity.
01:55:58.400
Oh, this has been a lot of fun. I'm glad I took the time to do this.
01:56:04.160
Thank you for listening to this week's episode of The Drive. If you're interested in diving deeper
01:56:08.300
into any topics we discuss, we've created a membership program that allows us to bring you
01:56:12.700
more in-depth exclusive content without relying on paid ads. It's our goal to ensure members get back
01:56:18.480
much more than the price of the subscription. Now to that end, membership benefits include
01:56:23.300
a bunch of things. One, totally kick-ass comprehensive podcast show notes that detail
01:56:28.180
every topic, paper, person, thing we discuss on each episode. The word on the street is
01:56:33.060
nobody's show notes rival these. Monthly AMA episodes or ask me anything episodes,
01:56:38.600
hearing these episodes completely. Access to our private podcast feed that allows you to
01:56:43.460
hear everything without having to listen to spiels like this. The qualies, which are a super
01:56:48.880
short podcast, typically less than five minutes that we release every Tuesday through Friday,
01:56:53.820
highlighting the best questions, topics, and tactics discussed on previous episodes of The Drive.
01:56:58.400
This is a great way to catch up on previous episodes without having to go back and necessarily
01:57:02.940
listen to everyone. Steep discounts on products that I believe in, but for which I'm not getting paid
01:57:08.860
to endorse, and a whole bunch of other benefits that we continue to trickle in as time goes on.
01:57:14.000
If you want to learn more and access these member-only benefits, you can head over to
01:57:17.400
peteratiamd.com forward slash subscribe. You can find me on Twitter, Instagram, and Facebook,
01:57:24.460
all with the ID peteratiamd. You can also leave us a review on Apple Podcasts or whatever podcast
01:57:30.960
player you listen on. This podcast is for general informational purposes only and does not
01:57:36.120
constitute the practice of medicine, nursing, or other professional healthcare services,
01:57:40.600
including the giving of medical advice. No doctor-patient relationship is formed.
01:57:45.600
The use of this information and the materials linked to this podcast is at the user's own risk.
01:57:51.640
The content on this podcast is not intended to be a substitute for professional medical advice,
01:57:56.840
diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice
01:58:02.940
from any medical condition they have, and they should seek the assistance of their healthcare
01:58:07.560
professionals for any such conditions. Finally, I take conflicts of interest very seriously. For all
01:58:14.120
of my disclosures and the companies I invest in or advise, please visit peteratiamd.com forward slash
01:58:21.540
about where I keep an up-to-date and active list of such companies.